References
- Lundstrom K. Self-replicating RNA viruses for RNA therapeutics. Molecules. 2018;23:E3310. doi: 10.3390/molecules23123310
- Strauss JH, Strauss EG. The alphaviruses: gene expression, replication and evolution. Micobiol Rev. 1994;58:491–562.
- Lundstrom K. RNA viruses as tools in gene therapy and vaccines development. Genes (Basel). 2018;10:E189.
- Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR) retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther. 2007;15:677–686.
- Martikainen M, Niittykoski M, von Und Zu Frauenberg M, et al. MicroRNA-attenuated clone of virulent Semliki forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma. J Virol. 2015;89:10637–10647.
- Ying H, Zaks TZ, Wang R-F, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med. 1999;5:823–827.
- Moran TP, Burgents JE, Long B, et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine. 2007;25:6604–6612.
- Velders MP, McElhiney S, Cassetti MC, et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 2001;61:7861–7867.
- Draghiciu O, Boerma A, Hoogeboom BN, et al. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology. 2015;4:e1029699.
- Yin X, Wang W, Zhu X, et al. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochem Biophys Res Comm. 2015;465:239–244.
- Urbiola C, Santer FR, Petersson M, et al. Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer. Int J Cancer. 2018 Apr 26;143:1786–1796. [ Epub ahead of print].
- Morse MA, Hobelka AC, Osada T, et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Investig. 2010;120:3234–3241.
- Slovin SF, Kehoe M, Durso R, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013;31:943–949.
- NCT00390299. Viral therapy in treating patients with recurrent glioblastoma multiforme. NIH, Bethesda, MD; USA, 2008. Available from November 21, 2018: http://www.clinicaltrials.gov/ct2/show/NCT00390299.
- Galanis E, Hartmann LC, Cliby W, et al. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). J Clin Oncol. 2008;26(15S):Abs 5538.
- Dispenzieri A, Tong C, La Plant B, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 2017;31:2791–2798.
- Heinzerling L, Künzi V, Oberholzer PA, et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood. 2005;106:2287–2294.
- Lundstrom K. Biology and application of alphaviruses in gene therapy. Gene Ther. 2005;12(Suppl. 1):S92–S97.
- Lollini P-L, Cavallo F, Nanni P, et al. The promise of preventive cancer vaccines. Vaccines (Basel). 2015;3:467–489.
- Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505–518.
- Vogel AB, Lambert L, Kinnear E, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26:446–455.
- Van de Wall S, Ljungberg K, Ip PP, et al. Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. Oncoimmunology. 2018;7:e1487913.